Referred to the House Committee on Armed Services.
This bill (Rx ACCESS Act) amends Title 10 to change TRICARE pharmacy benefit rules. It allows eligible beneficiaries beginning October 1, 2026 to elect receiving non‑generic maintenance medications through any authorized dispensing method, requires TRICARE pharmacy benefit contracts to reimburse retail pharmacies at least the pharmacy acquisition cost (actual cost or a NADAC-based proxy) plus a professional dispensing fee equal to the State Medicaid dispensing fee, and prohibits contractors from imposing point‑of‑sale, retroactive, or other hidden fees on TRICARE retail pharmacies.
Fiscal impact: liberals and centrists expect oversight and are willing to accept higher reimbursements if justified; conservatives worry mandates will raise taxpayer costs and constrain contracting.
Modest, targeted benefit/contracting change for military beneficiaries could attract bipartisan support in the House, especially among members focused on military benefits; however, visible industry opposition (PBMs/contractors) and fiscal concerns about higher TRICARE costs raise obstacles and potential floor amendments.
This bill (Rx ACCESS Act) amends Title 10 to change TRICARE pharmacy benefit rules.
It allows eligible beneficiaries beginning October 1, 2026 to elect receiving non‑generic maintenance medications through any authorized dispensing method, requires TRICARE pharmacy benefit contracts to reimburse retail pharmacies at least the pharmacy acquisition cost (actual cost or a NADAC-based proxy) plus a professional dispensing fee equal to the State Medicaid dispensing fee, and prohibits contractors from imposing point‑of‑sale, retroactive, or other hidden fees on TRICARE retail pharmacies.
The bill also mandates annual Government Accountability Office audits of reimbursement data and network adequacy (including rural and underserved access and continuity of care) and requires the contractor to provide information for those audits.
On substance the bill is narrow, directly benefits military beneficiaries, and can be operationalized through defense contracting—factors that favor enactment or incorporation into larger defense legislation. Offsetting factors include likely opposition from contracted pharmacy benefit managers and fiscal conservatives, absence of explicit cost offsets, and procedural barriers in the Senate. Inclusion as a provision of a larger defense/appropriations vehicle would materially raise the chance of enactment.
How solid the drafting looks.
Fiscal impact: liberals and centrists expect oversight and are willing to accept higher reimbursements if justified; conservatives worry mandates will raise taxpayer costs and constrain contracting.
These are examples from the analysis, not a ranked list of the most-affected groups.
Fiscal impact: liberals and centrists expect oversight and are willing to accept higher reimbursements if justified; conservatives worry mandates will raise taxpayer costs and constrain contracting.
A mainstream progressive would likely view this bill largely positively because it expands beneficiary choice, increases transparency around pharmacy benefit manager (PBM) practices, and raises minimum reimbursement standards that could help independent and rural pharmacies.
They would appreciate the GAO auditing requirement as a tool to document access gaps and contractor behavior.
Some progressives may be cautious about potential increases in DoD pharmacy spending if higher reimbursements raise program costs, and they would want assurances that savings are not offset by cutting other benefits or that costs are fairly apportioned.
A pragmatic centrist would view the bill as a targeted reform with potentially constructive goals—improving beneficiary choice, curbing opaque PBM practices, and strengthening oversight—but would focus on the affordability and operational feasibility of the changes.
They would want to know projected budget impacts for the Department of Defense and whether contract terms can be implemented without disrupting access or increasing costs to beneficiaries.
The annual GAO audit and requirement for an implementation plan are viewed favorably as mechanisms to measure effects and allow midcourse corrections.
A mainstream conservative would likely have mixed feelings.
The expansion of beneficiary choice and protections for retail pharmacies could be attractive, especially for support of local businesses and service members’ autonomy.
At the same time, imposing contract conditions (specific reimbursement formulas tied to acquisition cost or NADAC and mandatory parity with state Medicaid dispensing fees) and banning contractor fees may be viewed as federal micromanagement of procurement and could raise spending or legal concerns.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is narrow, directly benefits military beneficiaries, and can be operationalized through defense contracting—factors that favor enactment or incorporation into larger defense legislation. Offsetting factors include likely opposition from contracted pharmacy benefit managers and fiscal conservatives, absence of explicit cost offsets, and procedural barriers in the Senate. Inclusion as a provision of a larger defense/appropriations vehicle would materially raise the chance of enactment.
The bill has not accumulated any surfaced votes yet.
Fiscal impact: liberals and centrists expect oversight and are willing to accept higher reimbursements if justified; conservatives worry ma…
On substance the bill is narrow, directly benefits military beneficiaries, and can be operationalized through defense contracting—factors t…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Rx ACCESS Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.